Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Infections: A Multicenter Cohort Study

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Date 2025 Jan 25

PMID 39861170

Authors

Thamer A Almangour

Zakiyah Alkherb

Leen Ghonem

Mohammed Al Musawa

Abdullah Almohaizeie

Sara Almuhisen

Aminah Alharbi

Nader Damfu

Doaa Aljefri

Jeelan Alghaith

Awaly Alfozan

Ahlam AlGhamdi

Ahmad Aljabri

Abdullah A Alhifany

Mohammed Alessa

Yazed Saleh Alsowaida

Affiliations

Soon will be listed here.

Abstract

To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) infections. This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR infections. Outcomes were compared using multivariate logistic regression analysis. Among the screened patients, 203 patients were included: 89 in the CAZ-AVI group and 114 in the colistin group. A total of 57% presented with pneumonia, 21% with bacteremia, and 61% were in the intensive care unit. The rate of clinical cure was significantly higher among patients who received CAZ-AVI (67% vs. 50%; OR, 2.07; 95% CI, 1.16-3.68). The rate of in-hospital mortality was numerically lower among patients who received CAZ-AVI (40% vs. 49%; OR, 0.58; 95% CI, 0.33-1.03). The rate of AKI was significantly lower among patients who received CAZ-AVI (15% vs. 43%; OR, 0.23; 95% CI, 0.11-0.45). CAZ-AVI was more effective in treating MDR infections and showed a better safety profile compared to colistin. Thus, CAZ-AVI could be a better alternative for treating MDR infections.

References

Alatoom A, Alattas M, Alraddadi B, Ayoub Moubareck C, Hassanien A, Jamal W . Antimicrobial Resistance Profiles of Pseudomonas aeruginosa in the Arabian Gulf Region Over a 12-Year Period (2010-2021). J Epidemiol Glob Health. 2024; 14(3):529-548. PMC: 11442796. DOI: 10.1007/s44197-024-00191-y. View

Almangour T, Aljabri A, Al Musawa M, Almohaizeie A, Almuhisen S, Damfu N . Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob Antimicrob Resist. 2022; 28:288-294. DOI: 10.1016/j.jgar.2022.01.023. View

Oliota A, Penteado S, Tonin F, Fernandez-Llimos F, Sanches A . Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019; 94(1):41-49. DOI: 10.1016/j.diagmicrobio.2018.11.008. View

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

Tumbarello M, Trecarichi E, Corona A, De Rosa F, Bassetti M, Mussini C . Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2018; 68(3):355-364. DOI: 10.1093/cid/ciy492. View

Matuschek E, Ahman J, Webster C, Kahlmeter G . Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2017; 24(8):865-870. DOI: 10.1016/j.cmi.2017.11.020. View

Almangour T, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N . Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study. Infect Drug Resist. 2022; 15:211-221. PMC: 8807865. DOI: 10.2147/IDR.S349004. View

Tsuji B, Pogue J, Zavascki A, Paul M, Daikos G, Forrest A . International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of.... Pharmacotherapy. 2019; 39(1):10-39. PMC: 7437259. DOI: 10.1002/phar.2209. View

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciad428. View

10.

Almangour T, Alruwaili A, Almutairi R, Alrasheed A, Alhifany A, Eljaaly K . Aerosolized plus intravenous colistin vs intravenous colistin alone for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria: A retrospective cohort study. Int J Infect Dis. 2021; 108:406-412. DOI: 10.1016/j.ijid.2021.06.007. View

11.

Caston J, Lacort-Peralta I, Martin-Davila P, Loeches B, Tabares S, Temkin L . Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017; 59:118-123. DOI: 10.1016/j.ijid.2017.03.021. View

12.

Kadri S, Adjemian J, Lai Y, Spaulding A, Ricotta E, Prevots D . Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018; 67(12):1803-1814. PMC: 6260171. DOI: 10.1093/cid/ciy378. View

13.

Shortridge D, Gales A, Streit J, Huband M, Tsakris A, Jones R . Geographic and Temporal Patterns of Antimicrobial Resistance in Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016. Open Forum Infect Dis. 2019; 6(Suppl 1):S63-S68. PMC: 6419917. DOI: 10.1093/ofid/ofy343. View

14.

Pogue J, Kaye K, Veve M, Patel T, Gerlach A, Davis S . Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2019; 71(2):304-310. DOI: 10.1093/cid/ciz816. View

15.

Salman J, Dabal L, Bassetti M, Alfouzan W, Al Maslamani M, Alraddadi B . Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. Int J Antimicrob Agents. 2020; 56(4):106104. DOI: 10.1016/j.ijantimicag.2020.106104. View

16.

Stone G, Newell P, Gasink L, Broadhurst H, Wardman A, Yates K . Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018; 73(9):2519-2523. DOI: 10.1093/jac/dky204. View

17.

Moghnieh R, Kanafani Z, Tabaja H, Sharara S, Awad L, Kanj S . Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018; 18(12):e379-e394. DOI: 10.1016/S1473-3099(18)30414-6. View

18.

Alhifany A, Alqurashi A, Al-Agamy M, Alkhushaym N, Alhomoud F, Alhomoud F . Employment of Mapping Technology in Antimicrobial Resistance Reporting in Saudi Arabia. Geospat Health. 2020; 15(1). DOI: 10.4081/gh.2020.868. View

19.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

20.

ODonnell J, Bidell M, Lodise T . Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections. Pharmacotherapy. 2020; 40(9):952-969. DOI: 10.1002/phar.2449. View